Quality by Design (QbD) Approach to Develop Colon-Specific Ketoprofen Hot-Melt Extruded Pellets: Impact of Eudragit^® S 100 Coating on the In Vitro Drug Release.

IF 4.9 3区医学 Q1 PHARMACOLOGY & PHARMACY

Pharmaceutics Pub Date : 2024-09-27 DOI:10.3390/pharmaceutics16101265

Sateesh Kumar Vemula, Sagar Narala, Prateek Uttreja, Nagarjuna Narala, Bhaskar Daravath, Chamundeswara Srinivasa Akash Kalla, Srikanth Baisa, Siva Ram Munnangi, Naveen Chella, Michael A Repka

{"title":"Quality by Design (QbD) Approach to Develop Colon-Specific Ketoprofen Hot-Melt Extruded Pellets: Impact of Eudragit® S 100 Coating on the In Vitro Drug Release.","authors":"Sateesh Kumar Vemula, Sagar Narala, Prateek Uttreja, Nagarjuna Narala, Bhaskar Daravath, Chamundeswara Srinivasa Akash Kalla, Srikanth Baisa, Siva Ram Munnangi, Naveen Chella, Michael A Repka","doi":"10.3390/pharmaceutics16101265","DOIUrl":null,"url":null,"abstract":"Background: A pelletizer paired with hot-melt extrusion technology (HME) was used to develop colon-targeted pellets for ketoprofen (KTP). Thermal stability and side effects in the upper gastrointestinal tract made ketoprofen more suitable for this work.Methods: The pellets were prepared using the enzyme-triggered polymer Pectin LM in the presence of HPMC HME 4M, followed by pH-dependent Eudragit® S 100 coating to accommodate the maximum drug release in the colon by minimizing drug release in the upper gastrointestinal tract (GIT). Box-Behnken Design (BBD) was used for response surface optimization of the proportion of different independent variables like Pectin LM (A), HPMC HME 4M (B), and Eudragit® S 100 (C) required to lower the early drug release in upper GIT and to extend the drug release in the colon.Results: Solid-state characterization studies revealed that ketoprofen was present in a solid solution state in the hot-melt extruded polymer matrix. The desired responses of the prepared optimized KTP pellets obtained by considering the designed space showed 1.20% drug release in 2 h, 3.73% in the first 5 h of the lag period with the help of Eudragit® S 100 coating, and 93.96% in extended release up to 24 h in the colonic region.Conclusions: Hence, developing Eudragit-coated hot-melt extruded pellets could be a significant method for achieving the colon-specific release of ketoprofen.","PeriodicalId":19894,"journal":{"name":"Pharmaceutics","volume":"16 10","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11509973/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/pharmaceutics16101265","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: A pelletizer paired with hot-melt extrusion technology (HME) was used to develop colon-targeted pellets for ketoprofen (KTP). Thermal stability and side effects in the upper gastrointestinal tract made ketoprofen more suitable for this work.

Methods: The pellets were prepared using the enzyme-triggered polymer Pectin LM in the presence of HPMC HME 4M, followed by pH-dependent Eudragit^® S 100 coating to accommodate the maximum drug release in the colon by minimizing drug release in the upper gastrointestinal tract (GIT). Box-Behnken Design (BBD) was used for response surface optimization of the proportion of different independent variables like Pectin LM (A), HPMC HME 4M (B), and Eudragit^® S 100 (C) required to lower the early drug release in upper GIT and to extend the drug release in the colon.

Results: Solid-state characterization studies revealed that ketoprofen was present in a solid solution state in the hot-melt extruded polymer matrix. The desired responses of the prepared optimized KTP pellets obtained by considering the designed space showed 1.20% drug release in 2 h, 3.73% in the first 5 h of the lag period with the help of Eudragit^® S 100 coating, and 93.96% in extended release up to 24 h in the colonic region.

Conclusions: Hence, developing Eudragit-coated hot-melt extruded pellets could be a significant method for achieving the colon-specific release of ketoprofen.

查看原文本刊更多论文

用质量源于设计（QbD）的方法开发结肠特异性酮洛芬热熔挤出颗粒：Eudragit® S 100 涂层对体外药物释放的影响。

背景：使用造粒机和热熔挤出技术（HME）来开发酮洛芬（KTP）的结肠靶向颗粒。上消化道的热稳定性和副作用使酮洛芬更适合这项工作：方法：在 HPMC HME 4M 存在下，使用酶触发聚合物果胶 LM 制备颗粒，然后进行 pH 依赖性 Eudragit® S 100 包衣，以通过最大限度减少上消化道（GIT）的药物释放来适应结肠的最大药物释放量。采用盒-贝肯设计（BBD）对果胶 LM（A）、HPMC HME 4M（B）和 Eudragit® S 100（C）等不同自变量的比例进行了响应面优化，以降低药物在上消化道的早期释放并延长药物在结肠中的释放：固态表征研究表明，酮洛芬在热熔挤出聚合物基质中呈固溶状态。在 Eudragit® S 100 包衣的帮助下，制备的优化 KTP 颗粒在 2 小时内的药物释放率为 1.20%，在滞后期的前 5 小时内释放率为 3.73%，在结肠区域的药物释放时间延长至 24 小时，释放率为 93.96%：因此，开发Eudragit包衣热熔挤出颗粒是实现酮洛芬结肠特异性释放的重要方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmaceutics Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

7.90

自引率

11.10%

发文量

2379

审稿时长

16.41 days

期刊介绍： Pharmaceutics (ISSN 1999-4923) is an open access journal which provides an advanced forum for the science and technology of pharmaceutics and biopharmaceutics. It publishes reviews, regular research papers, communications, and short notes. Covered topics include pharmacokinetics, toxicokinetics, pharmacodynamics, pharmacogenetics and pharmacogenomics, and pharmaceutical formulation. Our aim is to encourage scientists to publish their experimental and theoretical details in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.